

Reference number(s) 2851-A

# Initial Prior Authorization Motegrity

## **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated

Brand Name	Generic Name
Motegrity	prucalopride

### **Indications**

#### **FDA-approved Indications**

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

## **Coverage Criteria**

#### Chronic Idiopathic Constipation (CIC)

Authorization may be granted when the requested drug is being prescribed for the treatment of chronic idiopathic constipation (CIC) in an adult patient.

## **Duration Of Approval (DOA)**

• 2851-A: DOA: 36 months

Motegrity PA 2851-A 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

#### References

- 1. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November 2020.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 10, 2024.
- 3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/10/2024).

## **Document History**

Written by: UM Development (DS)

Date Written: 12/2018

Revised: 09/2019 (no clinical changes); (PM) 08/2020 (no clinical changes); (EC) 07/2021 (no clinical changes); (VLS) 09/2022 (no clinical changes); (SS) 09/2023 (no clinical changes); (DMH) 09/2024 (no clinical changes)

Reviewed: Medical Affairs (EPA) 01/2019; (CHART) 09/26/2019, 09/24/2020, 09/30/2021, 09/22/2022,

09/28/2023, 09/26/2024

External Review: 02/2019, 12/2019, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024

#### **CRITERIA FOR APPROVAL**

1 Is the requested drug being prescribed for the treatment of chronic idiopathic Yes No constipation (CIC) in an adult patient?
[No further questions]

Mapping Instructions				
	Yes	No	DENIAL REASONS	
1.	Approve, 36	Deny	Your plan only covers this drug when it is used for certain health	
	Months		conditions. Covered use is for chronic idiopathic constipation (CIC)	
			in an adult. Your plan does not cover this drug for your health	
			condition that your doctor told us you have. We reviewed the	
			information we had. Your request has been denied. Your doctor	
			can send us any new or missing information for us to review. For	
			this drug, you may have to meet other criteria. You can request the	
			drug policy for more details. You can also request other plan	

Motegrity PA 2851-A 10-2024\_RMotegrity PA 2851-A 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
2851-A

	documents for your review.
	[Short Description: Diagnosis]

Motegrity PA 2851-A 10-2024\_RMotegrity PA 2851-A 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.